Phase 4 Type 2 Diabetes Trial, Recruiting NCT07112339 Sponsor: Novo Nordisk A/S Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 4 Type 2 Diabetes Trial, Recruiting

NCT07112339
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were diagnosed with type 2 diabetes at least 180 days (about 6 months) before the screening visit.
  • People who are currently taking one or more of certain diabetes medications that are not insulin, such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or several other approved diabetes tablets or injections (confirm with trial site for the full list).
  • People whose diabetes management, in the opinion of the trial doctor, needs to be strengthened by adding a long-acting (basal) insulin.
  • People who have had an HbA1c blood sugar result of 7% or higher recorded within the 90 days before joining the trial.

Who may not be able to join:

  • People who have a known or suspected allergy or sensitivity to the study medication or similar products.
  • People who have previously signed a consent form for this same study.
  • Women who are pregnant, breastfeeding, planning to become pregnant, or who are able to become pregnant and are not using an adequate form of contraception.
  • People who have taken part in another interventional clinical trial and received a study treatment within the 90 days before the screening visit.
  • People who have any other health condition that the trial doctor believes could put their safety at risk.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Phone: (+1) 866-867-7178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
15 August 2025
Est. completion
4 August 2026

Where this trial is recruiting

🇨🇦 Canada 🇩🇪 Germany 🇮🇹 Italy

Primary endpoints

Change in glycated haemoglobin (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov